Hoffmann A, Schmalz M, Leineweber M
Hoechst AG, Pharma Research/H 825, Frankfurt/M, Germany.
Biochim Biophys Acta. 1996 Jan 5;1299(1):95-102. doi: 10.1016/0005-2760(95)00201-4.
The potent hypolipidemic activity of HOE 402 (4-amino-2-(4, 4-dimethyl-2-oxo-1-imidazolidinyl)pyrimidine-5-N-(trifluoromethyl-phenyl ) carboxamide monohydrochloride), which was previously demonstrated in rat and rabbit, was investigated in noncholesterol and cholesterol fed male hamsters. In normolipidemic hamsters fed a low cholesterol chow diet containing 0.10% or 0.15% HOE 402 for 3 weeks, the plasma total cholesterol level fell by 13% and 20% respectively, but no effect on hepatic total cholesterol content was detected. Hepatic sterol synthesis was increased 3-fold in hamsters fed 0.15% HOE 402. In hamsters fed a chow diet containing 0.25% cholesterol for 3 weeks, the plasma cholesterol level increased to 226 mg/dl (compared to 123 mg/dl in their chow fed controls) and the liver cholesterol content was 26.2 mg/g compared to 2.3 mg/g in the control group. However, 0.15% HOE 402 led to a 48% reduction and 0.20% HOE 402 to a 80% reduction, in total hepatic cholesterol concentration. There was a 43% fall in plasma cholesterol level being observed with the higher HOE 402 dose. Using the dual isotope plasma ratio method, no inhibition of intestinal cholesterol absorption by HOE 402 was found, either in the noncholesterol fed or in the cholesterol fed hamsters. Cholesterol feeding diminished the whole LDL animal clearance to 393 +/- 17 microliters/h per 100 g animal (control 666 +/- 81 microliters/h per 100 g). When treated with 0.20% HOE 402, the whole animal LDL clearance rate was enhanced 2.3-fold to 824 +/- 66 microliters/h per 100 g. In the hamsters fed 0.25% cholesterol alone whole liver LDL receptor activity was suppressed to 63 +/- 5%, compared to that in the untreated controls (100%). The addition of 0.20% HOE 402 to the cholesterol enriched diet not only reversed this suppression, but resulted in a marked stimulation of liver receptor activity to 165 +/- 15% (whole body LDL receptor activity 141 +/- 10%). These results indicate that HOE 402 exerts its lipid lowering effect by a more direct activation on hepatic LDL receptor activity rather than by an indirect intestinal effect on cholesterol absorption.
HOE 402(4-氨基-2-(4,4-二甲基-2-氧代-1-咪唑烷基)嘧啶-5-N-(三氟甲基苯基)甲酰胺盐酸盐)具有显著的降血脂活性,此前已在大鼠和兔子身上得到证实,本研究对喂食非胆固醇和胆固醇饲料的雄性仓鼠进行了相关研究。在喂食含0.10%或0.15% HOE 402的低胆固醇饲料3周的正常血脂仓鼠中,血浆总胆固醇水平分别下降了13%和20%,但未检测到对肝脏总胆固醇含量有影响。喂食0.15% HOE 402的仓鼠肝脏固醇合成增加了3倍。在喂食含0.25%胆固醇饲料3周的仓鼠中,血浆胆固醇水平升至226毫克/分升(其对照的正常饲料喂养仓鼠为123毫克/分升),肝脏胆固醇含量为26.2毫克/克,而对照组为2.3毫克/克。然而,0.15% HOE 402使肝脏总胆固醇浓度降低了48%,0.20% HOE 402使其降低了80%。较高剂量的HOE 402使血浆胆固醇水平下降了43%。采用双同位素血浆比值法,未发现HOE 402对喂食非胆固醇饲料或胆固醇饲料的仓鼠肠道胆固醇吸收有抑制作用。喂食胆固醇会使整个动物的低密度脂蛋白(LDL)清除率降至每100克动物393±17微升/小时(对照为每100克动物666±81微升/小时)。用0.20% HOE 402处理后,整个动物的LDL清除率提高了2.3倍,达到每100克动物824±66微升/小时。在仅喂食0.25%胆固醇的仓鼠中,整个肝脏LDL受体活性被抑制至63±5%,与未处理的对照组(100%)相比。在富含胆固醇的饲料中添加0.20% HOE 402不仅逆转了这种抑制作用,还导致肝脏受体活性显著刺激至165±15%(全身LDL受体活性为141±10%)。这些结果表明,HOE 402通过更直接地激活肝脏LDL受体活性而非通过对胆固醇吸收的间接肠道作用来发挥其降血脂作用。